18.00
1.23 (7.33%)
1.23 (7.33%)
Upgrade to Real-Time
Afterhours (Closed)
| Volume | 376,452 |
|
|||||
| News | - | ||||||
| Day High | 18.46 | Low High |
|||||
| Day Low | 16.29 | ||||||
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Aclaris Therapeutics Inc | ACRS | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
 |
|
|---|---|---|---|---|
| 1.23 | 7.33% | 18.00 | 00:00:01 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 16.42 | 16.29 | 18.46 | 18.00 | 16.77 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 5,859 | 376,452 | $ 17.92 | $ 6,747,566 | - | 9.26 - 19.97 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:01:43 | 96 | $ 18.00 | USD |
Period:
Draw Mode:
Aclaris Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 1.20B | 66.58M | 64.17M | $ 6.76M | $ - | -1.63 | -10.40 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 411.78k | 4.20% |
Aclaris Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ACRS Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 15.73 | 18.46 | 13.43 | 14.76 | 327,543 | 2.27 | 14.43% |
| 1 Month | 16.68 | 18.46 | 13.43 | 15.33 | 244,437 | 1.32 | 7.91% |
| 3 Months | 10.39 | 18.46 | 10.32 | 14.31 | 365,522 | 7.61 | 73.24% |
| 6 Months | 11.23 | 18.59 | 9.84 | 14.54 | 434,987 | 6.77 | 60.28% |
| 1 Year | 14.14 | 19.97 | 9.26 | 14.63 | 431,828 | 3.86 | 27.3% |
| 3 Years | 1.12 | 30.375 | 0.70 | 10.81 | 853,764 | 16.88 | 1,507.14% |
| 5 Years | 26.72 | 30.375 | 0.70 | 11.16 | 681,456 | -8.72 | -32.63% |
Aclaris Therapeutics Description
| Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777. |